Avenacy intros generic Reglan

Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, is offering metoclopramide injection, which is a generic of ANI's Reglan.

Metoclopramide Injection is indicated for the relief of symptoms associated with diabetic gastroparesis, the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, the prevention of postoperative nausea and vomiting, small bowel intubation and radiological examination.

“In the ten months since launching as a new specialty pharmaceutical company, Avenacy has made unprecedented progress in delivering critical injectable medications to the U.S. market at an industry-leading pace,” said Jeff Yordon, co-founder and CEO of Avenacy. 

[Read more: Avenacy releases magnesium sulfate in water for injection]

Yordon continued, “The launch of metoclopramide, our thirteenth commercial product, is the latest testament to our positive momentum and growing product register. Following the recent and significant capital infusion from our new equity investor, we are well-positioned to continue our strong trajectory by doubling down on growth initiatives that will allow us to expand our partner network, scale our business, and strengthen our commercial portfolio.”

Avenacy's Metoclopramide injection is available in 10 mg/2 ml (5 mg per ml) single-dose vials. In line with Avenacy’s mission to champion patient safety and streamline patient care, Metoclopramide Injection will feature the company’s highly differentiated packaging and labeling to support accurate medication selection.

The company shared that it is supported by a global network of development and contract manufacturing partners that has undergone successful FDA inspections based on cGMP-standards.

[Read more: Generic sterile injectables market to reach $196.2B by 2029]

Metoclopramide injection had a market value of approximately $12.7 million for the 12 months ending in June 2023, per IQVIA.